Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Inclusion Criteria:

1. Male or female participants ≥18 years of age.

2. History of ASCVD (coronary heart disease [CHD], cardiovascular disease [CVD], or
peripheral arterial disease [PAD]).

3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).

4. Fasting triglyceride <4.52 mmol/L (<400 mg/dL) at screening.

5. Participants on statins should be receiving a maximally tolerated dose.

6. Participants not receiving statins must have documented evidence of intolerance to all
doses of at least 2 different statins.

7. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a
stable dose for ≥30 days before screening with no planned medication or dose change
during study participation.

Exclusion Criteria:

1. New York Heart Association (NYHA) class IV heart failure.

2. Uncontrolled cardiac arrhythmia

3. Uncontrolled severe hypertension

4. Active liver disease

5. Females who are pregnant or nursing, or who are of childbearing potential and
unwilling to use at least 2 methods of highly effective contraception (failure rate
less than 1% per year) (for example, combined oral contraceptives, barrier methods,
approved contraceptive implant, long-term injectable contraception, or intrauterine
device) for the entire duration of the study. Exemptions from this criterion:

1. Women >2 years postmenopausal (defined as 1 year or longer since last menstrual
period) and more than 55 years of age.

2. Postmenopausal women (as defined above) and less than 55 years of age with a
negative pregnancy test within 24 hours of randomization.

3. Women who are surgically sterilized at least 3 months prior to enrollment.

6. Males who are unwilling to use an acceptable method of birth control during the entire
study period (such as condom with spermicide).

7. Treatment with other investigational products or devices within 30 days or 5
half-lives of the screening visit, whichever is longer.

8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards
PCSK9

The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.